RegulationOrphan Drug (United States), Priority Review (China), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China)

Structure/Sequence

Molecular FormulaC5H6N2

InChIKeyNUKYPUAOHBNCPY-UHFFFAOYSA-N

CAS Registry504-24-5

100

Clinical Trials associated with Dalfampridine

NCT04516603

/ WithdrawnPhase 2IIT

Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Healthy Subjects

Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants.
The hypotheses is that fampridine improves working memory performance.

Start Date01 Jan 2040

Sponsor / Collaborator

University of Basel

[+1]

NCT06751784

/ Not yet recruitingPhase 2IIT

Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Mild Depression

Cognitive deficits, including working memory deficits, are often present in depression and there are currently no effective pharmacological treatments targeting working memory deficits. Papassotiropoulos et al. (2024) has recently demonstrated that fampridine, a potassium channel blocker, can enhance working memory in healthy individuals with lower baseline performance, suggesting it may hold potential for addressing cognitive deficits in clinical populations. The primary aim of this study is to evaluate whether fampridine improves working memory performance in mild depression

Start Date01 Apr 2025

Sponsor / Collaborator

University of Basel

[+1]

NCT06003166

/ RecruitingPhase 3IIT

Pharmaco-Diagnostic Crossover Trial for Peripheral Nerve Continuity After Trauma

The purpose of this study is to evaluate the role of single dose 4-aminopyridine (4-AP) on the diagnosis of severing vs non-severing nerve injury after peripheral nerve traction and/or crush injury. The investigational treatment will be used to test the hypothesis that 4-aminopyridine can speed the determination of nerve continuity after peripheral nerve traction and/or crush injuries allowing the identification of incomplete injuries earlier than standard electrodiagnostic (EDX) and clinical assessment.
Participants will be randomized to one of two groups to determine the order of treatment they receive (drug and placebo vs placebo and drug). Participants will undergo baseline testing for nerve assessment, receive either drug or placebo based on randomization and undergo hourly sensory and motor evaluation, EDX testing and serum 4AP levels for three hours after dosing. Participants will then repeat this with the crossover arm.

Start Date01 Mar 2025

Sponsor / Collaborator

University of Arizona

[+1]

100 Clinical Results associated with Dalfampridine

100 Translational Medicine associated with Dalfampridine

100 Patents (Medical) associated with Dalfampridine

11,858

Literatures (Medical) associated with Dalfampridine

01 Jun 2025·Current Neuropharmacology

Modulation of in vitro Network Activity by Optogenetic Stimulation of Parvalbumin-positive Interneurons During Estrous Cycle

Article

Author: Wang, Siyan ; Lévesque, Maxime ; Gemayel, Mia ; Li, Fei Ran ; Avoli, Massimo

Background::

Catamenial epilepsy, which is defined as a periodicity of seizure exacerbation occurring during the menstrual cycle, has been reported in up to 70% of epileptic women. These seizures are often non-responsive to medication and our understanding of the relation between menstrual cycle and seizure generation (i.e. ictogenesis) remains limited.

Methods::

Here, we employed the in vitro 4-aminopyridine model of epileptiform synchronization, to analyze the effects induced by optogenetic activation of parvalbumin (PV)-positive interneurons at 8 Hz during estrous and non-estrous phases in female PV-ChR2 mice.

Results::

We found that: (i) optogenetic stimulation of PV-positive interneurons induced an initial interictal spike followed by field oscillations occurring more often in estrous (59%) than in non-estrous slices (17%); (ii) these oscillations showed significantly higher power in estrous compared to nonestrous slices (p < 0.001); (iii) significantly higher rates of interictal spikes and ictal discharges were identified in both estrous and non-estrous slices during optogenetic stimulation of PV-positive interneurons compared to periods of no stimulation (p < 0.05); and (iv) ictal events appeared to occur more frequently during optogenetic stimulation in estrous compared to non-estrous slices.

Conclusion::

Our findings show that optogenetic activation of PV-interneurons leads to more powerful network oscillations and more frequent ictal discharges in estrous than in non-estrous slices. We conclude that during the rodent estrous cycle, PV-interneuron hyperexcitability may play a role in epileptiform synchronization and thus in catamenial seizures.

01 May 2025·Neural Regeneration Research

Pharmacological intervention for chronic phase of spinal cord injury

Article

Author: Tohda, Chihiro

Spinal cord injury is an intractable traumatic injury. The most common hurdles faced during spinal cord injury are failure of axonal regrowth and reconnection to target sites. These also tend to be the most challenging issues in spinal cord injury. As spinal cord injury progresses to the chronic phase, lost motor and sensory functions are not recovered. Several reasons may be attributed to the failure of recovery from chronic spinal cord injury. These include factors that inhibit axonal growth such as activated astrocytes, chondroitin sulfate proteoglycan, myelin-associated proteins, inflammatory microglia, and fibroblasts that accumulate at lesion sites. Skeletal muscle atrophy due to denervation is another chronic and detrimental spinal cord injury–specific condition. Although several intervention strategies based on multiple outlooks have been attempted for treating spinal cord injury, few approaches have been successful. To treat chronic spinal cord injury, neural cells or tissue substitutes may need to be supplied in the cavity area to enable possible axonal growth. Additionally, stimulating axonal growth activity by extrinsic factors is extremely important and essential for maintaining the remaining host neurons and transplanted neurons. This review focuses on pharmacotherapeutic approaches using small compounds and proteins to enable axonal growth in chronic spinal cord injury. This review presents some of these candidates that have shown promising outcomes in basic research (in vivo animal studies) and clinical trials: AA-NgR(310)ecto-Fc (AXER-204), fasudil, phosphatase and tensin homolog protein antagonist peptide 4, chondroitinase ABC, intracellular sigma peptide, (-)-epigallocatechin gallate, matrine, acteoside, pyrvate kinase M2, diosgenin, granulocyte-colony stimulating factor, and fampridine-sustained release. Although the current situation suggests that drug-based therapies to recover function in chronic spinal cord injury are limited, potential candidates have been identified through basic research, and these candidates may be subjects of clinical studies in the future. Moreover, cocktail therapy comprising drugs with varied underlying mechanisms may be effective in treating the refractory status of chronic spinal cord injury.

01 Apr 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Ranolazine attenuates mouse detrusor contractility: Evidence for the involvement of calcium-related mechanisms

Article

Author: Sari, Suat ; Kadioglu, Mine ; Dağlar, Gökçe ; Barut, Elif Nur ; Engin, Seçkin ; Erac, Yasemin

Ranolazine (RNZ) is a multifaceted ion channel modulator approved for the treatment of angina. Although various pleiotropic effects on the cardiovascular system have been demonstrated, its efficacy in the urinary system remains not fully understood. Here, we aimed to investigate the effect of RNZ on mouse detrusor smooth muscle (DSM) contractility and the mechanism(s) of its action by using isolated tissue bath technique. RNZ significantly decreased carbachol (CCh)-, KCl- and electrical field stimulation-induced contractility and induced relaxation in DSM concentration-dependently. Furthermore, RNZ-induced relaxation of KCl-precontracted DSM strips was not altered in the presence of 4-aminopyridine, BaCl₂, glibenclamide, TEA, propranolol, L-NAME or methylene blue, indicating that K⁺ channels, nitric oxide/cGMP pathway or β-adrenoreceptors are not involved in the relaxant effect of RNZ. Also, RNZ significantly inhibited the contractile response induced by CaCl₂, CCh, and Bay K8644 under Ca⁺⁺-free conditions. Regarding the molecular docking and cytosolic Ca⁺⁺ mobilization assays, RNZ showed affinity for the antagonist binding site of L-type Ca⁺⁺ channels and significantly decreased cytosolic Ca⁺⁺ level in A7r5 cells. These findings suggest the inhibition of Ca⁺⁺ influx and release may contribute to RNZ-induced DSM relaxation. Hence, our results provide strong evidence that RNZ has a notable relaxant effect on mouse DSM by inhibiting Ca⁺⁺ influx and release of Ca⁺⁺ from intracellular stores and it has the potential to be a therapeutic candidate for LUTS.

News (Medical) associated with Dalfampridine

12 Feb 2025

·www.prnewswire.com

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

— Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — — ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN, Feb. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into a highly profitable, pure-play neuroscience company. We enter 2025 with a diversified portfolio of proprietary commercial products generating substantial profitability and an advancing development pipeline that represents a significant value creation opportunity in one of the most exciting potential new therapeutic categories in neuroscience," said Richard Pops, Chief Executive Officer of Alkermes. "Looking ahead, we are well positioned to deliver on our financial goals and advance the development programs for our portfolio of orexin 2 receptor agonists. This year, we have clear objectives for our pipeline as we complete the phase 2 studies for ALKS 2680 in narcolepsy, with data expected in the second half of the year, and prepare to initiate the ALKS 2680 phase 2 study in idiopathic hypersomnia and advance ALKS 4510 and ALKS 7290 into planned phase 1 studies in disease areas beyond central disorders of hypersomnolence. Each of these initiatives is an important element of our strategy to unlock what we believe is a multi-billion-dollar market opportunity for this category." "2024 was Alkermes' strongest year of financial and operational performance to date. Financially, we generated more than $1 billion in revenue from our proprietary commercial product portfolio, delivered EBITDA from continuing operations of approximately $452 million, repurchased $200 million of the company's ordinary shares, retired approximately $290 million of debt and ended the year debt-free with approximately $825 million of cash and investments on the balance sheet. Operationally, we completed the sale of our manufacturing business in Ireland and made significant progress advancing our neuroscience development pipeline," said Blair Jackson, Chief Operating Officer of Alkermes. "We will continue to manage the business with a sharp focus on efficiency and profitability as we invest in the programs that we believe will drive the company's next phase of growth." Key Financial Highlights *As a result of the successful resolution of the arbitration with Janssen Pharmaceutica N.V., the twelve months ended December 31, 2023 included approximately $195.4 million of back royalties (and related interest) related to U.S. net sales of long-acting INVEGA® products that would ordinarily have been recognized in prior periods. Revenue Highlights LYBALVI Revenues for the fourth quarter were $77.0 million. Fourth quarter revenues and total prescriptions grew 37% and 30%, respectively, compared to the fourth quarter of 2023. During the quarter, the company recorded LYBALVI® revenue of approximately $4 million related to year-end inventory fluctuations. ARISTADAi Revenues for the fourth quarter were $96.6 million. Fourth quarter revenues grew 16% compared to the fourth quarter of 2023. During the quarter, the company recorded ARISTADA® revenue of approximately $9 million related to year-end inventory fluctuations and gross-to-net favorability, primarily driven by Medicaid utilization adjustments. VIVITROL Revenues for the fourth quarter were $134.1 million. Fourth quarter revenues grew 31% compared to the fourth quarter of 2023. During the quarter, the company recorded VIVITROL® revenue of approximately $23 million related to year-end inventory fluctuations and gross-to-net favorability, primarily driven by Medicaid utilization adjustments. Manufacturing & Royalty Revenues Royalty revenues from XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® for the fourth quarter were $36.5 million. VUMERITY® manufacturing and royalty revenues for the fourth quarter were $35.0 million. FAMPYRA® manufacturing and royalty revenues for the fourth quarter were $22.9 million. The company does not expect to record any FAMPYRA revenue going forward. RISPERDAL CONSTA® manufacturing revenues for the fourth quarter were $14.7 million. Key Operating Expenses Please see Note 1 below for details regarding discontinued operations. Balance Sheet At Dec. 31, 2024, the company recorded cash, cash equivalents and total investments of $824.8 million, compared to $813.4 million at Dec. 31, 2023. In December 2024, the company prepaid and retired in full all of its outstanding long-term debt in the amount of approximately $290 million. Financial Expectations for 2025 All line items are according to GAAP, except as otherwise noted. Notes and Explanations 1. The company determined that upon the separation of its former oncology business, completed on Nov. 15, 2023, the oncology business met the criteria for discontinued operations in accordance with Financial Accounting Standards Board Accounting Standards Codification 205, Discontinued Operations. Accordingly, the accompanying selected financial information has been updated to present the results of the oncology business as discontinued operations for the three and twelve months ended Dec. 31, 2023. Conference Call Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. EST (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at . The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at . Non-GAAP Financial Measures This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income, EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. Non-GAAP net income adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; change in the fair value of contingent consideration; certain other one-time or non-cash items; and the income tax effect of these reconciling items. EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense in addition to the components of EBITDA from earnings. The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income, EBITDA and Adjusted EBITDA should not be considered measures of the company's liquidity. A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. Note Regarding Forward-Looking Statements Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects, including expected drivers of growth, value creation and profitability; and the company's expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, ALKS 2680 and the company's other orexin portfolio candidates. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the company is able to achieve its financial expectations, including those related to profitability; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the unfavorable outcome of arbitration, litigation, or other proceedings or disputes related to the company's products or products using the company's proprietary technologies; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's most recent Annual Report on Form 10-K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at . Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release. VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI®, INVEGA®, INVEGA HAFYERA®, INVEGA TRINZA®, RISPERDAL CONSTA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies; FAMPYRATM is a trademark of Merz Pharmaceuticals, LLC; and VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license. Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 SOURCE Alkermes plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Financial StatementPhase 1Phase 2

11 Jul 2024

·www.pharmaceutical-technology.com

Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%

Fampyra used to see sales of over $500m in 2017, but sales weakened after generics entered the market. Image credit: Shutterstock / Elena Abrazhevich. Merz Therapeutics has successfully acquired Acorda’s Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) after the latter went bankrupt earlier this year. The sale was via a “stalking horse” bid, meaning the assets could have gone for more than the $185m opening bid by Merz. These types of bids are used in cases involving bankrupt companies. No competing company joined the auction, however, and Merz closed the transaction at the opening bid value. Merz said the addition of Inbrija and Ampyra, the latter marketed as Fampyra (fampridine) outside of the US, would “immediately add topline revenue” and enhance the biotech’s ability to expedite clinical development of other assets, as per a 10 July press release. Merz’s lead product is Xeomin (incobotulinumtoxinA), used to treat excessive drooling, upper limb spasticity, and cervical dystonia, among others. Inbrija meanwhile is used to treat patients with Parkinson’s disease while Ampyra / Fampyra is approved to help improve walking ability in patients with multiple sclerosis. Merz CEO Stefan König said the deal “strengthens [the company’s] market position in Parkinson’s disease” while “expanding into the multiple sclerosis segment”. See Also: BARDA and Tiba Biotech link to develop ‘flu therapeutics Can a ‘super pill’ help shrink Big Pharma’s climate footprint? Merz also expects to increase its US workforce by more than 50% to support the newly added assets. Inbrija and Fampyra generated global sales of $31m and $73m, respectively, last year. According to GlobalData’s Pharma Intelligence Centre, Fampyra used to see sales of over $500m in 2017. But once it lost exclusivity in 2018, generics flooded the market, and sales weakened. GlobalData is the parent company of Pharmaceutical Technology . Merz forecasts its US business to contribute more than 75% of total global revenues for Inbrija and Fampyra over the next decade. Acorda used to be a big player in the neurodegenerative disorder space up until a few years ago. The formerly listed biotech at one point had $363m to spare when it decided to acquire Finnish biopharma Biotie Therapies , a developer of Parkinson’s disease therapies, in 2016. However, in subsequent years, Acorda struggled financially as sales of its drugs weakened. Biogen , which had a 2009 licence agreement for Fampyra outside the US, returned the rights to Acorda earlier this year. Shares in the company continued to dive and Acorda ultimately filed for bankruptcy, announced via a 1 April press release. In addition, Acorda was delisted from the Nasdaq Stock Market in mid-April, and closed its doors for the final time last month, leaving 97 employees at its New York site out of work.

AcquisitionLicense out/inDrug Approval

16 Apr 2024

·www.pharmaceutical-technology.com

Acorda loses Nasdaq listing to cap biotech’s end

Trading in Acorda’s stock was suspended on 12 April. Image credit: Shutterstock/NPS_87. Acorda Therapeutics has been delisted from the Nasdaq Stock Market as a result of non-compliance with Nasdaq’s listing rules. Nasdaq listing rules stipulate that companies maintain stockholders’ equity of at least $10m. As Acorda can no longer meet this requirement due to the company’s recent bankruptcy filing earlier this month, trading in the company’s common stock was suspended on 12 April, with Acorda reporting the delisting on 15 April. The absence on Nasdaq caps the company’s journey to the end of the twilight zone. The biotech’s closure date is set for 15 June, leaving the remaining 97 employees at its site in New York without a job, as per a labour notice filing . Over the past decade, Acorda saw success with its drugs for neurological disorders. Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) — also marketed as Fampyra (fampridine) outside of the US — were the company’s lead assets. Inbrija is used to treat patients with Parkinson’s disease while Ampyra/Fampyra is approved to help improve the walking ability of patients with multiple sclerosis. According to GlobalData’s Pharma Intelligence Centre, Fampyra used to see sales of more than $500m in 2017. However, after losing exclusivity to generics in 2018, Inbrija and Fampyra sales dropped to $31m and $73m respectively in 2023. See Also: Influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine by Sinovac Biotech for Seasonal Influenza: Likelihood of Approval INZ-701 by Inozyme Pharma for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD): Likelihood of Approval GlobalData is the parent company of Pharmaceutical Technology. Acorda struggled to balance the books as sales of its drugs weakened. Amid poor drug sales, Biogen, which had a 2009 licence agreement for Fampyra outside the US, exercised an option to the rights to Acorda earlier this year. Acorda responded to financial difficulty by laying off much of its workforce but its share values continued to dive, with a bankruptcy filing occurring in April 2024. Merz Therapeutics, known for its Botox rival Xeomin (incobotulinumtoxinA), swooped in a day later to buy Acorda’s assets , including Inbrija and Ampyra. Merz acted as a “stalking horse” bidder, a type of bid used in cases involving bankrupt companies. As it stands, Merz is set to acquire the therapies for $185m, though this could increase if another bidder comes in at a higher price. The sale process is expected to end in June 2024.

VaccineDrug ApprovalLicense out/inAcquisition

100 Deals associated with Dalfampridine

External Link

KEGG	Wiki	ATC	Drug Bank
D04127	Dalfampridine	N07XX07	DB06637

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis	United States	Merz Pharma GmbH & Co. KGaA	22 Jan 2010
Multiple Sclerosis	United States	Merz Pharmaceuticals LLC	22 Jan 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ischemic stroke	Phase 3	United States	Acorda Therapeutics, Inc.	01 Dec 2014
Ischemic stroke	Phase 3	Canada	Acorda Therapeutics, Inc.	01 Dec 2014
Multiple Sclerosis, Primary Progressive	Phase 3	Japan	Biogen, Inc.	01 Aug 2013
Multiple Sclerosis, Relapsing-Remitting	Phase 3	Japan	Biogen, Inc.	01 Aug 2013
Multiple Sclerosis, Secondary Progressive	Phase 3	Japan	Biogen, Inc.	01 Aug 2013
Optic Neuritis	Phase 3	United States	Acorda Therapeutics, Inc.	01 May 2011
Muscle Spasticity	Phase 3	United States	Acorda Therapeutics, Inc.	01 Jun 2002
Muscle Spasticity	Phase 3	Canada	Acorda Therapeutics, Inc.	01 Jun 2002
Spinal Cord Injuries	Phase 3	United States	Acorda Therapeutics, Inc.	01 Jun 2002
Spinal Cord Injuries	Phase 3	Canada	Acorda Therapeutics, Inc.	01 Jun 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECTRIMS2023	Not Applicable	Multiple Sclerosis	50	Fampridine	rzduzpfjah(lfmpsmyhmf) = Despite these widespread benefits only 37.5% of responders improved their EQ-5D score iotuleiwgn (scvftbqywj ) View more	Positive	30 Sep 2023
P10-3.008 (AAN2023)	Not Applicable	Fatigue dopamine- \| noradrenaline- \| serotonin	45	Fampridine	xyhejobaez(saqdnmdxwk) = vqzwwbkoxa bfceoacoml (snglqihaum )	Positive	25 Apr 2023
				Amantadine	xyhejobaez(saqdnmdxwk) = bizyywggns bfceoacoml (snglqihaum )
NCT03847545 (MUST, Pubmed \| Clin Biomech (Bristol, Avon))	Not Applicable	Multiple Sclerosis	14	Fampridine treatment	grbvbaumxv(qypyotphqy) = kqgchosdvc fniswewffg (rkgmzfqgvr ) View more	-	17 Nov 2022
DDDR-35 (SNO2022)	Not Applicable	Glioblastoma Multiforme KCNA1	3	4-aminopyridine (4-AP)	eqqrwyrofg(unmmzfzuyc) = khewopzjnl memhuhqddx (kjceplsfmh )	Positive	14 Nov 2022
				4-aminopyridine (4-AP) + Fractionated Radiation	eqqrwyrofg(unmmzfzuyc) = cdcafodgyp memhuhqddx (kjceplsfmh )
ECTRIMS2022	Not Applicable	Multiple Sclerosis	4,972	Fampridine	evgfvawcnk(vtlsrkcbje) = vgvlhvknfm oznuxsylgq (osmzgolsdj, 0.13 - 0.37) View more	Positive	12 Oct 2022
NCT04026568 (CTgov)	Phase 2/3	Nerve injury \| Wounds and Injuries	1	4-Aminopyridine (Single Dose 4AP)	zvgjokpfsh(skgcbtmgiv) = hdgrfognro lhcwpzfrxh (ilrdenkiny, bvqnndjonk - jikvqmowjo) View more	-	14 Sep 2022
				Placebo oral tablet (Placebo)	srkqjwlysg = fspmvzsszs egfkakuang (vrpvtilpwl, gfvbzauxqm - relwubwabs) View more
ACTRIMS2022	Not Applicable	Multiple Sclerosis	-	Dalfampridine	qhojtmpfkf(xxwjrgbhii) = pxjjbsrpmo ijnmhgepil (aolujokamt ) View more	-	16 May 2022
				Placebo	qhojtmpfkf(xxwjrgbhii) = jwjlwtxvks ijnmhgepil (aolujokamt ) View more
NCT01480063 (LIBERATE, Pubmed \| CNS Drugs)	Not Applicable	Multiple Sclerosis	4,646	Prolonged-release fampridine (PR-FAM) 10-mg tablet	herafobdph(voweubfwpz) = Seventeen (< 1%) patients experienced actual events of seizure zezeglqezs (zilhqkvofw )	-	28 Jul 2021
NCT02208050 (CTgov)	Phase 4	Multiple Sclerosis, Primary Progressive \| Multiple Sclerosis, Secondary Progressive \| Multiple Sclerosis, Chronic Progressive	64	PR-Fampridine (PR-Fampridine)	upabktaffo = rulumipupd zjctdlrdnl (umiemsoxox, ebssfbgptf - exltunyhqn) View more	-	09 Jul 2021
				Placebo (Placebo)	upabktaffo = pyymuupddj yembwblcsn (xowxsmpekl, ybbapodify - vdmvvpulth) View more
NCT00056810 (Pubmed) Manual	Phase 2	Guillain-Barre Syndrome	12	4-aminopyridine	pgzwjnvhla(xeyikjgffq) = superior to placebo kthaaaoexi (kqnaounpep )	Positive	08 Apr 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis